Results 241 to 250 of about 11,127 (277)

Mepolizumab: A Review in Eosinophilic Asthma

BioDrugs, 2016
Mepolizumab (Nucala(®)) is a humanized monoclonal antibody against interleukin-5, a cytokine involved in the development, recruitment and activation of eosinophils (cellular mediators of airway inflammation, hyper-responsiveness and tissue remodelling).
openaire   +3 more sources

Persistence of Sinonasal Disease Despite Mepolizumab

The Journal of Allergy and Clinical Immunology: In Practice, 2020
The treatment paradigm for the management of chronic rhinosinusitis with nasal polyposis (CRSwNP) is currently undergoing a rapid evolution with the development of monoclonal antibody therapies targeted at type 2 inflammatory pathways. The use of these biologic therapies in asthmatic patients, and more recently, patients with CRSwNP has produced ...
Robert M. Naclerio, Nicholas R. Rowan
openaire   +3 more sources

Mepolizumab and Eosinophil-Mediated Disease

Current Medicinal Chemistry, 2009
Eosinophils are major pro-inflammatory cells that make a major contribution to diseases that affect the upper and lower airways, skin and gastrointestinal tract. Interleukin (IL)-5 is central to their maturation and release from the bone marrow together with their subsequent accumulation and activation in the tissues.
openaire   +2 more sources

Mepolizumab Effectiveness and Allergic Status in Real Life

International Archives of Allergy and Immunology, 2020
<b><i>Background:</i></b> It is not clear whether mepolizumab is differently effective in allergic and nonallergic severe eosinophilic asthmatics (SEA) in real life. <b><i>Objective:</i></b> We tested mepolizumab effectiveness in allergic/nonallergic SEA in real life.
Bruno Sposato, Marco Scalese, Gianna Camiciottoli, Giovanna Elisiana Carpagnano, Corrado Pelaia, Pierachille Santus, Mauro Maniscalco, Angelo Corsico, Amelia Grosso, Stefano Baglioni, Nicola Murgia, Ilenia Folletti, Girolamo Pelaia, Simonetta Masieri, Carlo Cavaliere, Antonino Musarra, Elena Bargagli, Alberto Ricci, Manuela Latorre, Pierluigi Paggiaro, Paola Rogliani   +20 more
openaire   +12 more sources

Mepolizumab in the treatment of eosinophilic esophagitis

Therapy, 2009
Mepolizumab is a humanized monoclonal antibody that binds specifically to and inactivates a protein cell messenger termed IL-5, which plays a major role in the proliferation, maturation, activation and survival of eosinophils. As a result, mepolizumab has been studied in a number of eosinophil-associated diseases, such as asthma, hypereosinophilic ...
Sandeep K. Gupta, Rana F. Ammoury
openaire   +2 more sources

Mepolizumab: First Global Approval

Drugs, 2015
Mepolizumab (Nucala(®)) is a fully humanized monoclonal antibody against interleukin-5 (IL-5) that is being developed by GlaxoSmithKline. Subcutaneous mepolizumab is approved in the USA for the add-on maintenance treatment of patients aged ≥12 years with severe asthma and an eosinophilic phenotype, and is awaiting approval in the EU. Mepolizumab blocks
openaire   +2 more sources

Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis

Expert Opinion on Biological Therapy, 2019
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis characterized by asthma, hypereosinophilia, and progressive multiorgan involvement. Although not fully elucidated, advancement in our understanding of the pathophysiology of EGPA has led to the development of multiple new ...
Jason Kihyuk Lee, Christian Pagnoux, Daniel Ennis   +2 more
openaire   +3 more sources

Mepolizumab in the Treatment of Severe Eosinophilic Asthma

Immunotherapy, 2015
IL-5 is crucial in the pathogenesis and evolution of eosinophilic asthma. Mepolizumab is a high-affinity humanized monoclonal antibody of the IgG1/k subtype that inhibits the binding of IL-5 to its receptor expressed on eosinophils, thereby inducing significant reduction in eosinophil circulation, as well as asthma exacerbations and corticosteroid ...
FAINARDI, Valentina, PISI, GIOVANNA, CHETTA, Alfredo Antonio   +2 more
openaire   +3 more sources

Mepolizumab-responsive Kimura disease

The Journal of Allergy and Clinical Immunology: In Practice, 2021
Manao Kinoshita, Youichi Ogawa, Misaki Onaka, Shinji Shimada, Tatsuyoshi Kawamura   +4 more
openaire   +3 more sources

Mepolizumab-based therapy in asthma

Current Opinion in Allergy & Clinical Immunology, 2015
There is considerable evidence that implicates eosinophils as important effector cells in the inflammation characteristic of eosinophilic asthma. IL-5 is central to eosinophil maturation and release from the bone marrow, their subsequent accumulation, activation and persistence in the tissues.
openaire   +3 more sources